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FDG-PET/CT is widely used to diagnose cardiac inflammation such as cardiac sarcoidosis. Physiological myocardial FDG uptake
often creates a problem when assessing the possible pathological glucose metabolism of the heart. Several factors, such as fasting,
blood glucose, and hormone levels, influence normal myocardial glucose metabolism. The effect of outdoor temperature on
myocardial FDG uptake has not been reported before. We retrospectively reviewed 29 cancer patients who underwent PET scans
in warm summer months and again in cold winter months. We obtained myocardial, liver, and mediastinal standardized uptake
values (SUVs) as well as quantitative cardiac heterogeneity and the myocardial FDG uptake pattern. We also compared age and
body mass index to other variables. The mean myocardial FDG uptake showed no significant difference between summer and
winter months. Average outdoor temperature did not correlate significantly with myocardial SUVmax in either summer or winter.
The heterogeneity of myocardial FDG uptake did not differ significantly between seasons. Outdoor temperature seems to have
no significant effect on myocardial FDG uptake or heterogeneity. Therefore, warming the patients prior to attending cardiac PET
studies in order to reduce physiological myocardial FDG uptake seems to be unnecessary.
1. Introduction
The 2-[18F]fluoro-2-deoxy-D-glucose (FDG) positron emis-
sion tomography combined with computed tomography
(PET-CT) is a widely used method for evaluating not only
cancer, but also other disorders such as inflammation [1].
The heart can use various substrates as oxidative fuel and
rapidly adapts its substrate utilisation to meet supply. Under
nonfasting conditions, the major source for myocardial
metabolism is fatty acids, but carbohydrates account for up
to 30% of the metabolism [2]. Fasting with or without a high-
fat, low-carbohydrate (HF-LCH) diet has been used to lower
the physiological glucose metabolism in the myocardium,
but there is no consensus over which protocol should be
used in the diagnosis of cardiac sarcoidosis or in the assess-
ment of cardiac viability [3]. Regulation of the myocardial
carbohydrate metabolism is complex, and in addition to
nutritional status, arterial substrates, and hormone levels,
coronary flow and the inotropic state of the myocardium
affect carbohydrate utilisation [4]. Results on the variability
of intraindividual physiological myocardial FDG uptake over
time remain controversial [5, 6], although in the clinical
setting variability can be substantial.
Sarcoidosis is a multisystem granulomatous disease that
can affect the myocardium in as many as 27% of cases [7].
Cardiac sarcoidosis is a potentially fatal condition and is asso-
ciated with a shorter median survival time [8]. However, the
diagnosis of cardiac sarcoidosis is demanding, and FDG-PET
has proved to be a valuable addition to the diagnostic chain
[9]. Thus, differentiating physiological from inflammatory
myocardial FDGuptake is vital. An abnormal pattern of FDG
uptake has been linked to myocardial pathologies; in cardiac
sarcoidosis, for example, a focal uptake is considered an indi-
cator of active disease [10]. In addition, greater heterogeneity
in the myocardial SUV associates with cardiac sarcoidosis
[11]. This tool could prove useful when interpreting cardiac
FDG-PET scans but requires more verification. If FDG
uptake in the normal myocardium varies greatly between
scans, it would affect the overall heterogeneity of FDG uptake
in the heart making interpretation more difficult. Seasonal
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variation in myocardial FDG uptake could be a factor to take
into account when diagnosing cardiac sarcoidosis.
To our knowledge, no published studies have assessed
the effect of outdoor temperature changes on myocardial
FDG uptake or heterogeneity. In countries with a long winter,
changes in temperature between seasons can be considerable.
Thus, the aim of this study was to assess seasonal variability
in myocardial FDG uptake.
2. Materials and Methods
2.1. Patients. The study, approved by the Helsinki University
Hospital Institutional Review Board, comprised 29 consecu-
tive patients referred to the Department of Nuclear Medicine
at the Helsinki University Hospital for a PET-CT imaging
as part of their routine diagnostic and/or treatment strategy
during summer 2009 and again in the winter of 2009-2010.
All patients referred to PET-CT had prior or suspected
cancer. The indications for a PET study were Hodgkin’s
lymphoma (𝑛 = 9); non-Hodgkin’s lymphoma (𝑛 = 2); head-
and-neck cancer (𝑛 = 8); ventricular carcinoma (𝑛 = 2);
rectosigmoid carcinoma (𝑛 = 2); cholangiocarcinoma (𝑛 =
2); esophageal carcinoma (𝑛 = 2); and pancreatic, renal, and
lung cancer (𝑛 = 1). One patient was suspected of having
carcinoma, but the final diagnosis was benign.The indication
for the second PET study was either treatment response
assessment or control of the previous findings. Of the 28
cancer patients, 6 underwent radiochemotherapy between
the two studies, 12 underwent chemotherapy, and 10 received
no treatment. None of the patients received radiotherapy to
the lower mediastinum affecting myocardium. All 12 patients
who received chemotherapy were treated with agents that
are potentially cardiotoxic, such as doxorubicin, cisplatin, 5-
fluorouracil, bevacizumab, and cyclophosphamide. However
it has been previously shown that these oncological treat-
ments do not affect the metabolic pattern of the myocardium
or heterogeneity in the FDG distribution in the left ventric-
ular walls [6]. All subjects were mobile outpatients and not
in-house and represented a typical patient for a PET scan
at our institution. We found BMI in our study population
to be normal (range between 18,5 and 24,9 kg/m2), but a
little lower than the average in Finland (21.5 ± 4.5, Finnish
average 26.6) (National Institute for Health and Welfare,
http://www.thl.fi/). Six subjects were under 16 years of age, 8
patients were underweight (BMI < 18.5 kg/m2), and 3 of these
were under 16 years of age; only 1 was considered overweight
(BMI > 30 kg/m2).
After the preliminary results, the patients were divided
into two groups based on their myocardial SUVs. Patient
Group 1 consisted of patients with a myocardial SUV higher
in the winter than in the summer (𝑛 = 16), and Group 2, the
opposite (𝑛 = 13).
2.2. PET-CT Imaging. The imaging protocol was identical for
each individual in both studies. Patients were advised to fast
for six hours prior to imaging. The blood glucose level was
monitored, but the data was not obtainable from the first PET
study as it was not routinely noted at the time. At the time
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Figure 1: Temperature range (C) in summer and winter months for
each study subject.
of the second PET study the mean blood glucose level of the
patients was 6,0mmol/L (108mg/dL) (SD ± 0,76, range 5,7–
7,8mmol/L). After an intravenous injection of 18F-FDG, the
patients rested for 60minutes in a semidarkened, quiet room.
We used a Gemini PET/CT scanner (Philips Inc., Cleveland,
OH, USA) to acquire the images. First, we obtained a CT
surview (30mA, 120 kVp). The patients were then scanned
from the base of the skull to midthigh (50mA, 120 kVp). We
then acquired the PET images in a standard-manner 8 cmbed
position at 1min 30 sec per frame.
2.3. Data and Image Analysis. The PET studies in June,
July, and August were considered a summer study and
those in January, February,March, November, andDecember
a winter study. We obtained average monthly and mean
daily temperatures from the Finnish Meteorological Institute
(http://www.ilmatieteenlaitos.fi/) (Figure 1) for Kaisaniemi
weather station in Helsinki. The mean outside temperature
change between the summer and winter studies was 24 (±7.1)
degrees Celsius.
Two experienced physicians of nuclear medicine (JS, AA)
evaluated the PET-CT images, which underwent quantita-
tive analysis after hand-driven ROIs were drawn over the
myocardium, mediastinum, and liver in order to obtain the
SUVmax values for each area. The ROIs were drawn over
the entire myocardium and partly over the mediastinum
and liver indicating regions of diffuse uptake. We calcu-
lated SUVmax ratios for the myocardium/mediastinum and
myocardium/liver.
We then analysed the PET-CT images also visually and
divided the patients into three categories (none/moderate/
intensive) depending on the intensity and distribution of
their myocardial FDG uptake (Figure 2). Changing from one
category in one study to another category in the other study
was considered a significant change in seasonal myocardial
FDG uptake (Figure 3).
We assessed the heterogeneity of the myocardial FDG
uptake according to the method previously described by
Tahara et al. [11]. We used the Carimas software package
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Figure 2: Different patterns of myocardial FDG distribution. (a) None, (b) moderate, and (c) intensive.
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Figure 3: Examples of variations in myocardial FDG uptake over
time. (a) “Intense” pattern both in summer and winter; (b) “none”
pattern in summer, but “intense” in winter; (c) “intense” in summer
and “none” in winter.
developed at the Turku PET Centre for quantitation of
cardiac PET studies to measure the SUVs of all of the 17
segments according to the statement of the American Heart
Association [12, 13]. We calculated the coefficient of variation
(CoV) of the myocardial SUV by dividing the standard
deviation (SD) of the SUV by the average SUV.
2.4. Statistical Analysis. Baseline variables and patient char-
acteristics appear as means, standard deviation (SD), and
range. In order to detect a clinically significant difference
in myocardial SUV and CoV between the two studies, SUV
2.8 and value of CoV 0.026 with an alpha value of 0.05
and a power of 80%, a total sample size of 29 patients was
calculated to be sufficient. We compared the myocardial
SUV and CoV in the summer months to those in the
winter months and estimated associations between variables
with Pearson’s correlation analysis. We performed a stepwise
Table 1: Characteristics of patients.
Number of patients 29
Male/female 19/10
Age mean ± SD (range) 47.9 ± 21.4 (10–72)
BMI mean ± SD (range) 21.5 ± 4.5 (14.9–34.0)
regression analysis in order to detect significant associations
between study variables and SUVs. An independent samples
𝑡-test was used to compare means between the two studies.
The myocardial SUV data in both summer and winter was
slightly skewed to the left, which means that logarithmic
transformation is notmandatory. All other data was normally
distributed.
3. Results
The characteristics of the study group are presented in
Table 1. The average monthly temperature was 18.1∘C in the
summer months and −1.5∘C in the winter months. The mean
daily temperature in the summer months was 20.2 ± 2.8∘C
and −3.8 ± 7.0∘C in the winter months, and the average
temperature change between summer and winter was 24.0
(±7.1)∘C. The injected FDG activity or the acquisition time
did not differ between summer and winter months. Table 2
summarises the variables.
We found no significant difference in the patients’
myocardial FDG uptake between the summer and winter
months (Figure 4).The difference in themyocardial SUVmax
between the two studies, the myocardium/mediastinal
SUVmax ratio, or the myocardium/liver SUVmax ratio was
nonsignificant. The difference remained insignificant when
looking only at patients over 16 years of age.
The average outdoor temperature did not correlate with
the myocardial SUV in the summer or winter months (𝑟 =
0.18; 𝑝 = 0.34 in summer; 𝑟 = −0.3, 𝑝 = 0.11 in
winter). Additionally, the difference between summer and
winter temperatures did not correlate with the difference in
themyocardial SUV between the summer andwintermonths
either (𝑟 = 0.12; 𝑝 = 0.55).
Themyocardial SUVmax in thewintermonthswas higher
than in the summermonths in 16 (55%) of the 29 patients.The
myocardial pattern was shifted upwards in 6 (38%) of these
16 patients, in 2 it shifted downwards, and in 8 it remained
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Table 2: Temperatures, SUVs, and coefficients of variation for the two scans.
First scan Second scan
𝑝 value
Mean (±SD) Mean (±SD)
Activity mean (MBq) 339 (58.5) 340 (57.0) 0.828
Acquisition (min) 62,9 (8.72) 60.5 (5.51) 0.234
Temperature mean (range) (∘C) 20.2 (15–26) −3.8 (−15–6)
SUVmyo 5.7 (±3.9) 6.2 (±4.6) 0.586
SUVmed 1.8 (±0.4) 1.8 (±0.2) 0.373
SUVliv 2.5 (±0.5) 2.6 (±0.5) 0.460
SUVmyo/med 3.2 (±2.2) 3.6 (±2.7) 0.478
SUVmyo/liv 2.4 (±1.8) 2.5 (±1.9) 0.796
Coefficient of variation 0.139 (±0.046) 0.134 (±0.050) 0.527
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Figure 4: Myocardial SUVmax change from summer to winter for
each subject.
stable. Of the 29 patients, 13 (45%) had a higher myocardial
SUVmax in the summer months; 7 (54%) of these 13 saw
a downward shift in the myocardial pattern group, and 6
remained stable with no upward shift. Two very young (10–
15 years old) subjects had active brown adipose tissue and a
higher myocardial SUV in summer than in winter.
The patients’ body mass index (BMI) had a positive
correlation with the myocardial SUV in the summer (𝑟 =
0,39, 𝑝 = 0.03) and especially in the winter (𝑟 = 0,45,
𝑝 = 0.01) months.
The heterogeneity of the myocardial SUV (CoV) mean
was 0.14 (±0.05) in summer and 0.13 (±0.05) in winter;
thus no significant difference in the heterogeneity between
the summer and winter months (𝑝 = 0.527) was found
(Figure 5). This was the case also when looking at the older
patient population (>16 years) only.
4. Discussion
Our study focused on the seasonal variability of glucose
metabolism of the myocardium. We compared intraindivid-
ual PET-CT studies performed at two time points: summer
and winter. In addition to visually assessing the intensity
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Figure 5: CoV of myocardial SUV in summer and in winter.
and pattern of the myocardial FDG uptake, we used semi-
quantitative analysis with SUV values for the myocardium,
mediastinum, and liver to obtain their ratios and calculated
myocardial SUV heterogeneity. We found no significant
difference in any of the parameters obtained between the
summer and winter studies. According to our findings,
warming the patients in order to diminish their physiological
myocardial FDG uptake prior to a cardiac FDG-PET study
seems unnecessary.
Certain patterns of FDG uptake in the myocardium are
associated with various pathological conditions. Ishimaru et
al. described different patterns of myocardial FDG uptake
and concluded that focal uptake is characteristic of patients
with cardiac sarcoidosis [10]. In a pictorial review, Lobert
et al. illustrated varied pathological FDG uptake patterns
associated with malignant conditions [14]. In our study, we
found no significant seasonal variability in myocardial FDG
patterns, so if the myocardial FDG pattern is considered
pathological, the time of year of the PET scan may be
irrelevant.
Tahara et al. assessed myocardial FDG uptake in 47 sub-
jects. Of these, 24 had systemic sarcoidosis and 12 had cardiac
involvement.The remaining 23 patientswere control subjects,
8 of whom had dilated cardiomyopathy.The authors used the
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coefficient of variation of SUV as a marker for heterogeneity
in the uptake. They found that the CoV was significantly
greater in patients with cardiac sarcoidosis than in control
or noncardiac sarcoidosis patients. They used a CoV cut-off
value of 0.18, which provides high sensitivity and specificity
for cardiac sarcoidosis (100% and 97%, resp.) [11]. In our
study, we found no significant difference in the heterogeneity
of myocardial FDG uptake between hot and cold months.
Our findings indicate that outdoor temperature has no signif-
icant effect on myocardial glucose uptake and heterogeneity,
so CoV can be used to assess cardiac sarcoidosis. This is an
important finding, since the issue may be relevant to a large
patient group; cardiac inflammatory processes are diagnosed
worldwide, from North America to Northern and Central
Europe, as well as in many Asian countries.
This almost automatic analysis method increases reliabil-
ity of the results because it reduces interoperator variability,
which can be substantial in visual analysis between operators
or even within an operator.
The myocardial metabolism is complex and can adapt
rapidly to changes in supply by shifting from one substrate to
another.Many factors, such as nutrition and hormonal status,
affect the mechanism of this process, which remains poorly
understood [2]. Environmental conditions are major factors
influencing the body and, consequently, the heart. Previous
studies have addressed the influence of age, blood glucose
level, fasting period, and dietary or pharmacological inter-
ventions on the myocardial glucose metabolism [3, 10, 15, 16].
There are ways to diminish myocardial glucose uptake and
to turn myocardial metabolism towards fatty acid utilisation.
Prolonged fasting for over 18 hours has proved effective [17],
but this is a very demanding protocol for a patient with a
serious illness such as cardiac sarcoidosis. Moreover, dietary
protocols and intravenous heparin injections are widely used
methods, but none of these have proved to be effective and
consensus on proper imaging protocol is still lacking.
Intraindividual variation in the physiological metabolism
of the myocardium could be a confounding factor when dif-
ferentiating benign physiological from pathological glucose
uptake in a PET scan with a glucose analog such as FDG.
Whether myocardial FDG uptake varies significantly within
individuals remains an open question. Khandani et al. found
high reproducibility of cardiac FDG uptake on serial scans
(intraclass correlation coefficient 0.77) in 47 patients, whereas
Inglese et al. found significant variability over time in global
myocardial FDG uptake and poor temporal reproducibility
of myocardial SUV on serial PET scans (ICC 0.61) [5, 6].
To our knowledge, this is the first study to consider
seasonal temperature changes as a factor affecting the glucose
metabolism of the heart. The outside temperature between
summer andwinter varies greatly in Finland, exposing people
to either very cold or very warm weather. The body adapts to
these changes in ambient temperature in various ways; brown
adipose tissue (BAT), for example, is known to be activated
during the colder months [18], so common practice in the
Nordic countries involves warming patients before scanning
in order to eliminate any distracting uptake.
We found no significant difference in myocardial FDG
uptake between warm summer months and cold winter
months. Our study population comprised nearly as many
subjects with a higher myocardial SUV in summer than in
winter as subjects with a higher myocardial SUV in winter.
The change inmyocardial SUVs between summer and winter
throughout the study population was quite dispersed, so
we observed no consistent change. Outside temperature or
changes in it therefore do not seem to be a significant factor
influencing the metabolism of the heart.
Standard protocol requires that patients rest at least one
hour before scanning, so in each case, they spend time
indoors prior to their PET study. If the heart is able to adapt
rapidly to warmer conditions, that is, within an hour, it could
influence our findings.
5. Limitations
Because the patients in our study were all cancer patients,
their fast lasted only 6 hours before the PET scan, contrary
to the longer, 12-hour fast used when assessing cardiac
inflammation such as CS. This is a minor limitation, as
the purpose of our study was to investigate intraindividual
physiological variation in myocardial FDG uptake.
We did not control the time each subject spent outdoors
before their scans. Our study aimed to compare scans taken
in different seasons and the effect of a long time exposure to
different ambient temperatures on myocardial FDG uptake.
All of the subjects in this study were mobile outpatients and
not in-house patients representative of a typical patient for a
PET scan at our institution.
We could not evaluate the possible effect of blood glucose
levels on the seasonal variation in myocardial FDG uptake,
since the blood glucose levels were not routinely noted at
the time of the first scans. At the time of the second scan,
however, we found no significant correlation between the
blood glucose levels and the myocardial SUVs.
6. Conclusion
In conclusion, our study shows that outside temperature
changes between seasons seem to have no significant effect
on myocardial FDG uptake. In addition, seasonal variance
in outside temperature does not affect heterogeneity of
myocardial FDG uptake. The glucose metabolism of the
myocardium does not react to seasonal temperature changes
in the same way as brown adipose tissue does, so such
temperature changes should not be a confounding factor
in myocardial FDG-PET studies, such as when a diagnosis
of cardiac sarcoidosis is in question. Warming the patients
prior to cardiac FDG-PET studies to lower the physiological
myocardial FDG uptake seems to be unnecessary.
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